Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
On Wednesday, Johnson & Johnson JNJ reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Lost Money on Johnson & Johnson(JNJ)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possi...
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson's nasal spray, Spravato (esketamine), to treat major depressive disorder.
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance
JNJ beats estimates for fourth-quarter earnings and sales. Its sales guidance for 2025 falls short of expectations.
J&J Tops Q4 Adjusted Earnings Estimates, But 2025 Sales Outlook Falls Short
Johnson & Johnson (JNJ) posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations while the company's sales projections for the coming fiscal year fell...
J&J's stock surrenders early gains as weak sales guidance offsets earnings beat
Medtech and drug company's 2025 sales guidance is below consensus
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson JNJ will release earnings results for its fourth quarter, before the opening bell on Wednesday, Jan. 22, 2025.
Q4 Earnings: 3 Consumer Staples Titans on Deck
Among the bunch of companies expected to report in the coming days include a few consumer staples titans such as Procter & Gamble, Johnson & Johnson, and Kimberly-Clark.
Investors Who Lost Money on Johnson & Johnson Should Contact Levi & Korsinsky About an Ongoing Investigation - JNJ
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possi...
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spr...
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-...
PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-base...
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. It remains to be seen if MedTech sales improved.
3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond
Dividend cuts can be devastating to an income-focused investor. You lose a portion of your passive income, and a dividend stock's price tends to fall significantly leading up to and after a payout ...
Related Companies